Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Protein prenylation plays a critical role in regulating the cellular localization of small GTPases and is essential for multiple myeloma (MM) pathology. Geranylgeranyl diphosphate synthase (GGPPS), producing a key prenylation moiety, exists in a dimeric or hexameric form, depending on the species. However, the functional significance of this oligomerization remains unclear. Using crystallography, mass spectrometry, and fluorescence spectroscopy, we show that the GGPPS mutant-found in the widely studied MM cell line RPMI-8226-exhibits weakened inter-dimer interactions, reduced hexamer stability, and increased apparent substrate affinity and product release kinetics. These effects are even more pronounced in a dimeric mutant, GGPPS, demonstrating that interdimer interactions within the hexamer help stabilize a lid region over the active site, thereby stabilizing product binding in an inhibitory conformation. Together, these findings reveal that hexamerization regulates GGPPS activity through product inhibition and underscore the importance of cell line selection and characterization in drug discovery efforts.

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.70181DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
8
product inhibition
8
ggpps
5
somatic multiple
4
myeloma mutation
4
mutation unravels
4
unravels mechanism
4
mechanism oligomerization-mediated
4
product
4
oligomerization-mediated product
4

Similar Publications

Bortezomib resistance in multiple myeloma (MM) is a significant clinical challenge that limits the long-term effectiveness. Currently, there is a lack of reliable biomarkers to predict bortezomib resistance. Previous studies reported that several proteins regulate bortezomib resistance through targeting ubiquitin-proteasome pathways, including heat shock protein family A member 9 (HSPA9), dickkopf Wnt signaling pathway inhibitor 1 (DKK1), proteasome 26S subunit non-ATPase 14 (PSMD14), and tripartite motif containing 21 (TRIM21).

View Article and Find Full Text PDF

Cereblon upregulation overcomes thalidomide resistance in multiple myeloma through mitochondrial functional reprogramming.

BMB Rep

September 2025

Basic Research Laboratory, Department of Physiology, College of Medicine, Smart Marine Therapeutic Center, Cardiovascular and Metabolic Disease Core Research Center, Inje University, Busan 47392, Korea; Department of Health Science and Technology, College of Medicine, Inje University, Busan 47392, K

Patients with multiple myeloma develop resistance to thalidomide during therapy, and the mechanisms to counteract thalidomide resistance remain elusive. Here, we explored the interaction between cereblon and mitochondrial function to mitigate thalidomide resistance in multiple myeloma. Measurements of cell viability, ATP production, mitochondrial membrane potential, mitochondrial ROS, and protein expression via western blotting were conducted in vitro using KSM20 and KMS26 cells to assess the impact of thalidomide on multiple myeloma.

View Article and Find Full Text PDF

Angiogenesis in Multiple Myeloma: 25 Years of Research in This Field.

Eur J Haematol

September 2025

Department of Translational Biomedicine and Neuroscience, University of Bari, Bari, Italy.

In 1994, Vacca, Ribatti, and colleagues demonstrated for the first time that bone marrow microvascular density was significantly increased in multiple myeloma (MM) compared to monoclonal gammopathies of undetermined significance (MGUS) and moreover in active vs. non-active forms. Starting from 1994, the aim of this review article is to summarize the most important acquisitions in the literature concerning the role of angiogenesis in MM progression and the possibility to use anti-angiogenic drugs in its treatment.

View Article and Find Full Text PDF

Advances in NK cell therapy for multiple myeloma.

Best Pract Res Clin Haematol

September 2025

Department of Hematology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, China. Electronic address:

Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally. In patients with MM, the number and function of NK cells are suppressed, resulting in reduced immune surveillance and clearance of myeloma cells. Restoring or enhancing the killing effect of NK cells on myeloma cells is an important strategy for MM immunotherapy.

View Article and Find Full Text PDF

Adoptive cellular therapies in multiple myeloma.

Best Pract Res Clin Haematol

September 2025

Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research - Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, Ion Chiricuta Cancer Center, Cluj Napoca, Romania. Electronic address:

Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved each year. Chimeric antigen receptor (CAR) therapies are an advanced form of immunotherapy that engineer T cells to recognize and destroy cancer cells.

View Article and Find Full Text PDF